secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2024-11-26T23:59:59+00:00
Accession:  0001213900-24-102833
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharmaceuticals effects 1-for-25 reverse stock split to regain Nasdaq bid price compliance
--------------------------------------------------------------------------------

- Reverse split at 1-for-25 ratio effective Nov 25, 2024; split-adjusted trading begins Nov 26.
- Authorized shares reduced from 400M to 16M; issued shares from ~193M to ~7.7M.
- No fractional shares issued; fractional interests rounded up to nearest whole share.
- Intended to regain compliance with Nasdaq minimum $1.00 bid price requirement.
- Trading symbol remains CTXR; new CUSIP 17322U306.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024102833/0001213900-24-102833-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024102833/ea0222380-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-102833

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer